Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Common corruption of the mTOR signaling network in human tumors.

Menon S, Manning BD.

Oncogene. 2008 Dec;27 Suppl 2:S43-51. doi: 10.1038/onc.2009.352. Review.

2.

LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Shaw RJ.

Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19. Review.

3.

Mammalian target of rapamycin: a central node of complex signaling cascades.

Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S.

Int J Clin Exp Pathol. 2011 Jun 20;4(5):476-95. Epub 2011 Jun 14. Review.

4.

Dysregulation of mTOR activity through LKB1 inactivation.

Zhou W, Marcus AI, Vertino PM.

Chin J Cancer. 2013 Aug;32(8):427-33. doi: 10.5732/cjc.013.10086. Epub 2013 May 14. Review.

5.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Gibbons JJ, Abraham RT, Yu K.

Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Review.

PMID:
19963098
6.

An expanding role for mTOR in cancer.

Guertin DA, Sabatini DM.

Trends Mol Med. 2005 Aug;11(8):353-61. Review.

PMID:
16002336
7.

Recent clinical trials of mTOR-targeted cancer therapies.

Don AS, Zheng XF.

Rev Recent Clin Trials. 2011 Jan;6(1):24-35. Review.

PMID:
20868343
8.

Functional consequences of mTOR inhibition.

Sudarsanam S, Johnson DE.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):31-40. Review.

PMID:
20047144
9.

Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.

Du W, Gerald D, Perruzzi CA, Rodriguez-Waitkus P, Enayati L, Krishnan B, Edmonds J, Hochman ML, Lev DC, Phung TL.

Lab Invest. 2013 Oct;93(10):1115-27. doi: 10.1038/labinvest.2013.98. Epub 2013 Aug 12.

10.

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL.

Cell. 2006 Sep 8;126(5):955-68.

11.

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.

Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Review.

PMID:
20569080
12.

Current status and challenges associated with targeting mTOR for cancer therapy.

Dowling RJ, Pollak M, Sonenberg N.

BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. Review.

PMID:
19489650
13.

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Shor B, Gibbons JJ, Abraham RT, Yu K.

Cell Cycle. 2009 Dec;8(23):3831-7. Epub 2009 Dec 14. Review.

PMID:
19901542
14.

mTOR signaling in cancer cell motility and tumor metastasis.

Zhou H, Huang S.

Crit Rev Eukaryot Gene Expr. 2010;20(1):1-16. Review.

15.

[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy.

De Giorgi U, Amadori D.

J Clin Oncol. 2010 May 20;28(15):e236-7; author reply e238. doi: 10.1200/JCO.2009.26.6866. Epub 2010 Feb 22. No abstract available.

PMID:
20177016
16.

mTOR signaling in glioblastoma: lessons learned from bench to bedside.

Akhavan D, Cloughesy TF, Mischel PS.

Neuro Oncol. 2010 Aug;12(8):882-9. doi: 10.1093/neuonc/noq052. Epub 2010 May 14. Review.

17.

A comprehensive map of the mTOR signaling network.

Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Perreault C, Roux PP, Kitano H.

Mol Syst Biol. 2010 Dec 21;6:453. doi: 10.1038/msb.2010.108. Review.

18.

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG.

J Clin Oncol. 2010 Feb 10;28(5):835-40. doi: 10.1200/JCO.2009.25.2981. Epub 2010 Jan 4.

19.

Targeting the mTOR pathway using deforolimus in cancer therapy.

Mahalingam D, Sankhala K, Mita A, Giles FJ, Mita MM.

Future Oncol. 2009 Apr;5(3):291-303. doi: 10.2217/fon.09.9. Review.

PMID:
19374536
20.

mTOR and cancer: many loops in one pathway.

Efeyan A, Sabatini DM.

Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.

Supplemental Content

Support Center